Clare L. Scott, MBBS, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses this year’s take-home messages in endometrial cancer. The AtTEnd trial (NCT03603184) tested atezolizumab, which was found to be effective (particularly in MMR deficient cases) alongside chemotherapy at extending progression-free survival. Patients who were MMR proficient (pMMR) or had MLH1 methylated cancers were equally benefiting. The RUBY trial (NCT03981796) was the first to provide updates across the four molecular subtypes of endometrial cancer, with the particularly aggressive p53 mutated subgroup performing surprisingly well; this has the potential to change the way we plan future studies and cater to patients’ unmet need. Additionally, advantages for pMMR groups were seen in the DUO-E trial (NCT04269200) with the use of a PARP inhibitor and DESTINY (NCT04482309) found extremely exciting outcomes in patients with HER2 aggressive cancers using trastuzumab deruxtecan (T-DXd) treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
